Advertisement
Advertisement
ACAD
Acadia Pharmaceuticals Inc.
27.15
USDSponsored
+1.54
+6.01%
Aug 04, 15:59 UTC -4
Closed
After-Market
27.36
+0.21
+0.79%
ACAD Earnings Reports
Positive Surprise Ratio
ACAD beat 28 of 43 last estimates.
65%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$331.86M
/$0.13
Implied change from Q2 26 (Revenue/ EPS)
+7.76%
/-27.78%
Implied change from Q3 25 (Revenue/ EPS)
+19.10%
/-69.05%
Acadia Pharmaceuticals Inc. earnings per share and revenue
On Aug 04, 2026, ACAD reported earnings of 0.18 USD per share (EPS) for Q2 26, beating the estimate of 0.05 USD, resulting in a 207.17% surprise. Revenue reached 307.96 million, compared to an expected 301.77 million, with a 2.05% difference.
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.13 USD, with revenue projected to reach 331.86 million USD, implying an decrease of -27.78% EPS, and increase of 7.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Arrowhead Research Corporation
Report Date
Aug 04, 2026 For Q3 26
Estimate
-$1.34
Actual
-$1.36
Surprise
-1.01%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.83
Actual
-$0.73
Surprise
+12.85%
Travere Therapeutics, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.37
Surprise
-161.48%
Ultragenyx Pharmaceutical Inc.
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$1.25
Actual
-$0.90
Surprise
+28.50%
Syndax Pharmaceuticals, Inc.
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.55
Surprise
-22.41%
Gilead Sciences Inc
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$7.37
Actual
-$6.75
Surprise
+8.53%
BioNTech SE - ADR
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$2.13
Actual
-$2.24
Surprise
-5.08%
Palvella Therapeutics, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
-$1.18
Actual
-$1.52
Surprise
-28.54%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
$1.01
Actual
$1.28
Surprise
+25.64%
Pacira BioSciences, Inc. Common Stock
Report Date
Aug 04, 2026 For Q2 26
Estimate
$0.66
Actual
$0.73
Surprise
+10.56%
FAQ
What were Acadia Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Acadia Pharmaceuticals Inc. reported EPS of $0.18, beating estimates by 207.17%, and revenue of $307.96M, 2.05% above expectations.
How did the market react to Acadia Pharmaceuticals Inc.'s Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Acadia Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Acadia Pharmaceuticals Inc.'s next earnings report?
Based on 7
analysts, Acadia Pharmaceuticals Inc. is expected to report EPS of $0.13 and revenue of $331.86M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement